First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in ...

Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...

In another press release, GSK announced that the CHMP has recommended expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent ...

在日本，GSK的呼吸道合胞病毒（RSV）疫苗Arexvy已获批用于50-59岁成年人。公司还报告了linerixibat的第三阶段GLISTEN试验的积极结果，该药物旨在治疗原发性胆汁性胆管炎患者的胆汁淤积性瘙痒。然而，由于预期2025年增长将趋于平缓，Jefferies和Guggenheim的金融分析师已下调了GSK的股票评级。

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.